Reaction
Metastases To Pelvis reporting signals
As of the last recalculation, Metastases To Pelvis appears in 623 FAERS reports alongside 34 co-occurring drug terms. The strongest observed disproportionality signal is RIBOCICLIB (PRR 97.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ribociclib | 80 | 97.0 | 97.3 |
| Goserelin | 32 | 83.9 | 84.1 |
| Exemestane | 41 | 68.4 | 68.5 |
| Fulvestrant | 59 | 65.8 | 65.9 |
| Anastrozole Tablets | 35 | 57.7 | 57.8 |
| Letrozole | 78 | 48.2 | 48.3 |
| Anastrozole | 48 | 47.2 | 47.3 |
| Octreotide Acetate | 40 | 46.6 | 46.6 |
| Letrozole Tablets | 60 | 46.0 | 46.1 |
| Regorafenib | 14 | 41.2 | 41.2 |
| Panitumumab | 17 | 37.2 | 37.3 |
| Zoledronic Acid | 30 | 26.2 | 26.2 |
| Niraparib | 15 | 23.1 | 23.1 |
| Olaparib | 14 | 22.8 | 22.9 |
| Everolimus Tablets | 11 | 22.3 | 22.3 |
| Bicalutamide | 10 | 22.3 | 22.3 |
| Erlotinib | 6 | 20.9 | 20.9 |
| Pazopanib Hydrochloride | 16 | 20.2 | 20.3 |
| Alpelisib | 5 | 19.3 | 19.3 |
| Everolimus | 27 | 18.5 | 18.5 |
| Lutetium Lu 177 Vipivotide Tetraxetan | 7 | 17.9 | 17.9 |
| Gemcitabine | 20 | 17.5 | 17.5 |
| Erlotinib Hydrochloride | 6 | 16.2 | 16.2 |
| Abiraterone | 6 | 14.9 | 14.9 |
| Leuprolide Acetate | 31 | 14.0 | 14.0 |
| Enzalutamide | 23 | 13.5 | 13.5 |
| Gemcitabine Hydrochloride | 20 | 13.0 | 13.0 |
| Osimertinib | 12 | 12.7 | 12.7 |
| Trifluridine And Tipiracil | 4 | 12.5 | 12.5 |
| Vemurafenib | 4 | 11.2 | 11.2 |
| Abiraterone Acetate | 12 | 9.9 | 9.9 |
| Palbociclib | 24 | 8.7 | 8.7 |
| Apalutamide | 3 | 8.6 | 8.6 |
| Durvalumab | 5 | 8.3 | 8.3 |